title: Comment on "Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: A randomized controlled trial" by Shihui Chen et al. [Dig. Liver Dis. 2015;47:226-32].
authors.affiliation: Liver Diseases Branch, NIDDK, NIH, Bethesda, USA. Electronic address: rotmany@mail.nih.gov.
authors.forename: Yaron
authors.initials: Y
authors.lastname: Rotman
mesh_terms: D001786:Blood Glucose / Q000187:drug effects*; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects*; D008297:Male; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D013267:Stilbenes